Aktuellt
SENASTE
At SEB's Nordic Seminar, we spoke with CEO Morten Albrechtsen, who noted the exciting news from this morning that lead drug FG001 has now demonstrated an ability to delineate tumours in patients across three different cancer types, with head and neck the latest. We expect phase 2 data in H1/23 from FluoGuide across all three cancers, and it is highly likely to be positive, which seems well timed vis-a-vis a likely easing of the equities bear market.
LÄS MER
